Legal & General Group PLC Immunic, Inc. Transaction History

Legal & General Group PLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 22, 2022	SELL	$3.13 - $12.25 $4,713 - $18,448	-1,506 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$8.05 - $13.29 $2,149 - $3,548	267 Added 21.55%	1,506 $13,000
Q2 2021 Aug 12, 2021	BUY	$11.76 - $16.85 $7,996 - $11,458	680 Added 121.65%	1,239 $15,000
Q1 2021 May 17, 2021	SELL	$14.21 - $25.3 $710 - $1,265	-50 Reduced 8.21%	559 $9,000
Q3 2020 Nov 13, 2020	BUY	$11.74 - $22.0 $1,185 - $2,222	101 Added 19.88%	609 $11,000
Q2 2020 Aug 14, 2020	BUY	$5.67 - $15.86 $2,880 - $8,056	508 New	508 $6,000
Q3 2019 Nov 13, 2019	SELL	$10.0 - $17.01 $1,140 - $1,939	-114 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$7.88 - $33.2 $898 - $3,784	114 New	114 $1,000

56.1M

4.7K

311K

Ticker IMUX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,565,000
Market Cap $50.4M
Description
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.